Cost-effectiveness of anti-vascular endothelial growth factor and macular laser treatments for people with centre-involving diabetic macular oedema and central retinal thickness of at least 400 micrometres.

چکیده

Diabetic macular oedema (DMO) is a common cause of vision loss and blindness. To inform the 2024 UK NICE guideline for treating people with centre-involving DMO (CI-DMO) and central retinal thickness (CRT) of ≥400 µm, the cost-effectiveness of various anti-vascular endothelial growth factor…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• رتینوپاتی دیابتی
• درمان های ضد VEGF
• شبکیه